Literature DB >> 15960599

Patterns of gene expression from in utero delivery of adenoviral-associated vector serotype 1.

Roberto Bilbao1, Daniel P Reay, Juan Li, Xiao Xiao, Paula R Clemens.   

Abstract

Adenoviral-associated viral vectors (AAV) have shown significant promise for efficient gene delivery to multiple tissues. Studies of different serotypes of AAV revealed different expression patterns provided by gene delivery in postnatal mice. Previous in utero gene delivery studies of AAV serotype 2 (AAV2) demonstrated efficient gene expression in certain fetal tissues depending on route of administration. We studied the pattern of gene expression from AAV serotype 1 (AAV1) using intramuscular, intraperitoneal, and intravascular routes of administration in embryonic day 16 C57BL/6 mice. Limb skeletal muscle transduction was only achieved with AAV1 by intramuscular administration. The levels of gene expression were 20-fold higher than a comparable administration of AAV2. Diaphragm muscle transduction by AAV1 was achieved at the highest level by intraperitoneal administration, and to a lesser degree by intravascular administration. All delivery routes resulted in transgene expression in the lung. Our results indicate that AAV1 can offer higher transgene expression in fetal skeletal muscle than AAV2 with intramuscular administration. The transgene expression pattern in different tissues, which depends on vector serotype and route of administration, will need to be considered in planning therapeutic studies for specific disorders.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15960599     DOI: 10.1089/hum.2005.16.678

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  8 in total

1.  Intra-amniotic rAAV-mediated microdystrophin gene transfer improves canine X-linked muscular dystrophy and may induce immune tolerance.

Authors:  Hiromi Hayashita-Kinoh; Naoko Yugeta; Hironori Okada; Yuko Nitahara-Kasahara; Tomoko Chiyo; Takashi Okada; Shin'ichi Takeda
Journal:  Mol Ther       Date:  2015-01-14       Impact factor: 11.454

2.  Correction of murine PKU following AAV-mediated intramuscular expression of a complete phenylalanine hydroxylating system.

Authors:  Zhaobing Ding; Cary O Harding; Alexandre Rebuffat; Lina Elzaouk; Jon A Wolff; Beat Thöny
Journal:  Mol Ther       Date:  2008-03-11       Impact factor: 11.454

3.  Frequency and spectrum of genomic integration of recombinant adeno-associated virus serotype 8 vector in neonatal mouse liver.

Authors:  Katsuya Inagaki; Chuncheng Piao; Nicole M Kotchey; Xiaolin Wu; Hiroyuki Nakai
Journal:  J Virol       Date:  2008-07-09       Impact factor: 5.103

4.  Systemic delivery of AAV8 in utero results in gene expression in diaphragm and limb muscle: treatment implications for muscle disorders.

Authors:  B M Koppanati; J Li; X Xiao; P R Clemens
Journal:  Gene Ther       Date:  2009-05-28       Impact factor: 5.250

5.  Factors determining the risk of inadvertent retroviral transduction of male germ cells after in utero gene transfer in sheep.

Authors:  Paul J Park; Evan Colletti; Ferhat Ozturk; Josh A Wood; Joe Tellez; Graça Almeida-Porada; Christopher Porada
Journal:  Hum Gene Ther       Date:  2009-03       Impact factor: 5.695

6.  Pseudotyped AAV vector-mediated gene transfer in a human fetal trachea xenograft model: implications for in utero gene therapy for cystic fibrosis.

Authors:  Sundeep G Keswani; Swathi Balaji; Louis Le; Alice Leung; Anna B Katz; Foong-Yen Lim; Mounira Habli; Helen N Jones; James M Wilson; Timothy M Crombleholme
Journal:  PLoS One       Date:  2012-08-24       Impact factor: 3.240

7.  Production and titering of recombinant adeno-associated viral vectors.

Authors:  Christina McClure; Katy L H Cole; Peer Wulff; Matthias Klugmann; Andrew J Murray
Journal:  J Vis Exp       Date:  2011-11-27       Impact factor: 1.355

8.  Kidney-specific expression of GFP by in-utero delivery of pseudotyped adeno-associated virus 9.

Authors:  Jason L Picconi; Melissa A Muff-Luett; Di Wu; Erik Bunchman; Franz Schaefer; Patrick D Brophy
Journal:  Mol Ther Methods Clin Dev       Date:  2014-05-07       Impact factor: 6.698

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.